Panther Chairman to Step Down for Health Reasons

CHICAGO, IL and LA JOLLA, CA--(Marketwired - Jun 1, 2015) - Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that Irwin "Izzy" Zalcberg has decided to retire from the Board of Directors of Panther Biotechnology to focus on his health. Evan Levine, the Company's President and Chief Executive Officer, will assume the Chairman role.

Mr. Zalcberg has started and participated in financings of dozens of companies. He is a survivor of Non-Hodgkin's Lymphoma, and is actively engaged in charities related to cancer. His experience of triumphing over this challenging condition was the impetus to launch Panther Biotechnology. However, the continual fight to strive for optimal health is requiring more dedicated time for himself and his family. Izzy remains a significant shareholder in Panther and continues to support the Company's business vision.

"The Company remains forever grateful for Izzy's initiatives and contributions" stated Evan Levine, Chief Executive Officer of Panther. "I would like to personally offer my sincere appreciation for Izzy's ingenuity and the opportunity not only for the growing team to participate in such an exciting opportunity but for the potential good to the community that can come from the Company's products under development. In 2015, Panther has executed agreements for three clinical candidates and a platform technology and is continuing to advance its business plan of analyzing new opportunities. We are also in negotiations for several other prospects that could add significant value to the portfolio. The Company has also been working diligently to bring its SEC filings current and plans to file its 10K and 10Q's in the next two weeks."

ABOUT PANTHER BIOTECHNOLOGY

Panther Biotechnology, Inc. is an entity focused on the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders. The Company is currently developing three clinical candidates, TRF-DOX which is a combination of transferrin glycoproteins with Doxorubicin for targeted delivery to tumors with the reduction of serious side effects, Numonafide, which is a derivative of the widely studied anticancer drug Amonafide optimized to eliminate toxic metabolites and reduce side effects, and TDZD-8, a kinase inhibitor targeting cancer stem cells. Panther is continuing its acquisition strategy focusing on identifying undervalued companies and clinical assets, including those programs that have missed clinical endpoints, and bring scientific and medical personnel capable of running the trials and extracting value from the assets.